Intravitreal Corticosteroid Implant for Extended Ocular Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetic retinopathy and diabetic macular edema, such as anti-VEGF therapy, require frequent injections and do not achieve complete resolution in a substantial proportion of cases, while corticosteroid therapy is effective but lacks extended release options, leading to a high patient treatment burden.
Innovation Solution
Development of extended-release corticosteroid compositions, including a complex of corticosteroids with fatty acids and keto-enol tautomers in a dispersal medium, formulated for intravitreal or periocular administration, providing sustained release profiles up to 12 months, using a biodegradable tube implant and complexation agents to control drug release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent injections of anti-VEGF therapy are administered, then treatment effectiveness for diabetic macular edema is improved, but patient treatment burden increases and adherence decreases
Solution Approach 1:
The patent implements continuous drug delivery through an implantable device that releases corticosteroids over an extended period (3-6 months), eliminating the need for frequent monthly injections. This continuous action maintains therapeutic drug levels in the vitreous humor while significantly reducing the number of patient visits and injections required, thereby resolving the contradiction between treatment effectiveness and patient burden
Solution Approach 2:
The implant is pre-loaded with a sustained-release formulation of corticosteroid before implantation, allowing the drug to be delivered over an extended period without requiring repeated administrations. This preliminary preparation of the drug delivery system enables long-term therapeutic action from a single implantation procedure
2Ease of operation
If extended release corticosteroid compositions are used, then injection frequency is reduced and treatment adherence improves, but device complexity increases
Solution Approach 1:
The patent utilizes phase change materials and temperature-responsive polymers that alter their physical properties (such as solubility, viscosity, or permeability) in response to temperature changes or other physiological parameters. This allows the implant to automatically regulate drug release rates without complex mechanical controls, achieving extended release while maintaining relatively simple device architecture
Solution Approach 2:
The sustained-release mechanism employs phase transitions of the corticosteroid formulation (such as crystalline-to-amorphous transitions or lipid phase changes) to control drug release kinetics. These physical phase changes provide a passive, self-regulating release mechanism that extends drug delivery over months without requiring complex active control systems, thus improving adherence while limiting device complexity
3Reliability
If corticosteroid therapy is administered, then inflammatory component of diabetic macular edema is targeted, but intraocular pressure may increase as a side effect
Solution Approach 1:
The implant delivers corticosteroids directly to the vitreous humor and retinal tissues where inflammatory pathology exists, creating a high local drug concentration at the site of action. This localized delivery maximizes anti-inflammatory efficacy while minimizing systemic exposure and reducing the risk of widespread side effects, including excessive intraocular pressure elevation, by confining the drug action to the specific ocular compartment needing treatment
Solution Approach 2:
The patent employs biodegradable polymer matrices and lipid-based carriers as intermediary materials that control the release and distribution of corticosteroids. These intermediary materials modulate the drug's pharmacokinetics, providing sustained release at lower doses and reducing peak concentration spikes that could trigger acute intraocular pressure increases, thereby maintaining therapeutic efficacy while mitigating harmful effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The extended-release corticosteroid compositions achieve therapeutic levels of corticosteroids in the eye for an extended period, reducing the frequency of injections and improving treatment adherence by providing sustained efficacy for diabetic retinopathy, macular edema, and other ocular conditions.
Implementation Method 1
a complex of the corticosteroid and a fatty acid in a dispersal medium as well as a complex of the corticosteroid and a keto-enol tautomer
Implementation Method 2
admixed in a dispersal medium so that the corticosteroid drug substance has a release profile having one or more phases of drug release
Implementation Method 3
releasing a therapeutically effective amount of the corticosteroid drug substance from the multiphasic colloidal suspension into a tissue
Data Source
AI summary
Corticosteroid compositions including a corticosteroid drug substance (e.g., fluocinolone, fluocinolone acetonide, dexamethasone, dexamethasone phosphate, dexamethasone sodium phosphate, triamcinolone, and triamcinolone acetonide) or a or a salt or derivative thereof and one or more irregular-shaped particulate fatty acid or keto-enol tautomer complexation agents admixed in a dispersal medium, having a release profile with one or more phases of drug release. These compositions are extended release corticosteroid compositions may release a clinically useful level of corticosteroid for more than 1 to 12 months within the body. Also described herein are methods of forming and methods of using these compositions.